Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 3, 2007, Pages 954-962

  Farré, Magí ^a,b   Abanades, Sergio ^a,b   Roset, Pere N ^a,b   Peiró, Ana M ^a,b   Torrens, Marta ^a,b   O'Mathúna, Bryan ^a,c   Segura, Mireia ^a,c   De La Torre, Rafael ^a,c  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXY 4 HYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYTOCHROME P450 2D6; METHAMPHETAMINE; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADULT; BLOOD PRESSURE; BODY TEMPERATURE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HALLUCINOGENS; HEART RATE; HUMANS; MALE; METABOLIC CLEARANCE RATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; PUPIL; SEROTONIN UPTAKE INHIBITORS;

EID: 36348943019     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.129056     Document Type: Article

References (39)

1. Battaglia G, Brooks BP, Kulsakdinun C, and De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-563.
2. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
3. Brauer LH, Rukstalis MR, and de Wit H (1995) Acute subjective responses to paroxetine in normal volunteers. Drug Alcohol Depend 39:223-230.
4. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, San L, and de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466.
5. Cleary L and Docherty JR (2003) Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. Eur J Pharmacol 476:31-34.
6. de la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo E, Pizarro N, Segura J, and Cami J (2000) Pharmacology of MDMA in humans. Ann NY Acad Sci 914:225-237.
7. Farré M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, and Camí J (1993) Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther 266:1364-1373.
8. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, and Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:364-375.
9. Green AR, Mechan AO, Elliott JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
10. Gudelsky GA and Nash JF (1996) Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
11. Hashimoto K, Maeda H, Hirai K, and Goromaru T (1993) Drug effects on distribution of [3H]3,4-methylenedioxymethamphetamine in mice. Eur J Pharmacol 228:247-256.
12. Hernández-López C, Farré M, Roset PN, Menoyo E, Pizarro N, Ortuño J, Torrens M, Camí J, and de la Torre R (2002) 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacology Exp Ther 300:236-244.
13. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, and Rostami-Hodjegan A (2004) Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32:1213-1217.
14. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, and Mikus G (2003) P-glycoprotein modulation by the designer drugs methylendioxymethamphetamine and paramethoxyamphetamine. Addict Biol 8:413-418.
15. Koch S and Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146.
16. Kotzailias N, Marker M, and Jilma B (2004) Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 24:536-539.
17. Lamas X, Farré M, Llorente M, and Cami J (1994) Spanish version of the 49-item short version of the Addiction Research Center Inventory (ARCI). Drug Alcohol Depend 35:203-209.
18. Liechti ME, Baumann C, Gamma A, and Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521.
19. Liechti ME and Vollenweider FX (2000a) Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10:289-295.
20. Liechti ME and Vollenweider FX (2000b) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274.
21. Mann H, Ladenheim B, Hirata H, Moran TH, and Cadet JL (1997) Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res 769:340-346.
22. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, and Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145.
23. McCann UD and Ricaurte GA (1993) Reinforcing subjective effects of (+/-) 3,4-Methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharmacol 13:214-217.
24. McDaid J and Docherty JR (2001) Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat. Br J Pharmacol 133:429-437.
25. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, and Green AR (2002) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135:170-180.
26. O'Shea E, Esteban B, Camarero J, Green AR, and Colado MI (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65-74.
27. Pacifici R, Pichini S, Zuccaro P, Farre M, Segura M, Ortuno J, Di Carlo S, Bacosi A, Roset PN, Segura J, et al. (2004) Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans. J Pharmacol Exp Ther 309:285-292.
28. Pizarro N, Ortuno J, Farre M, Hernández-Lopez C, Pujadas M, Llebaria A, Joglar J, Roset PN, Mas M, Segura J, et al. (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
29. Poudevida S, Farré M, Roset PN, and Camí J (2003) Construcción de un cuestionario para la Valoración de los Efectos Subjetivos de Sustancias con Potencial de Abuso (VESSPA): evaluación del éxtasis. Adicciones 15:115-126.
30. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
31. Rothman RB and Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88.
32. Sánchez C and Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-489.
33. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, and Colado MI (2001) The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134:46-57.
34. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7.
35. Segura M, Farre M, Pichini, S Peiro AM, Roset PN, Ramirez A, Ortuno J, Pacifici R, Zuccaro P, Segura J, et al. (2005) Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet 44:649-660.
36. Stein DJ and Rink J (1999) Effects of "Ecstasy" blocked by serotonin reuptake inhibitors. J Clin Psychiatry 60:485.
37. Tancer M and Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189:565-573.
38. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
39. Weiss J, Dormann S-M G, Martin-Facklam M, Dormann SM, and Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197-204.